182,200 Shares in Bruker Corporation (NASDAQ:BRKR) Bought by ING Groep NV

Key Points

• ING Groep NV has invested approximately $7.61 million in Bruker Corporation, acquiring 182,200 shares, which represents 0.12% ownership in the company.
• Bruker's stock has seen several analysts revise their price targets, with an average target of $53.10 and an overall rating of "Hold" from six analysts.
• Bruker recently reported a EPS of $0.32 for the last quarter, missing estimates by $0.11, with a revenue of $797.40 million compared to an expectation of $811.17 million.

ING Groep NV purchased a new stake in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 182,200 shares of the medical research company's stock, valued at approximately $7,605,000. ING Groep NV owned approximately 0.12% of Bruker as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of BRKR. London Co. of Virginia raised its stake in shares of Bruker by 78.4% in the fourth quarter. London Co. of Virginia now owns 4,193,454 shares of the medical research company's stock valued at $245,820,000 after acquiring an additional 1,843,294 shares during the period. Sculptor Capital LP raised its stake in shares of Bruker by 484.1% in the fourth quarter. Sculptor Capital LP now owns 1,714,015 shares of the medical research company's stock valued at $100,476,000 after acquiring an additional 1,420,569 shares during the period. FIL Ltd raised its stake in shares of Bruker by 262.3% in the fourth quarter. FIL Ltd now owns 1,961,416 shares of the medical research company's stock valued at $114,978,000 after acquiring an additional 1,420,102 shares during the period. Steadfast Capital Management LP purchased a new stake in shares of Bruker in the fourth quarter valued at $63,997,000. Finally, Marshall Wace LLP raised its stake in shares of Bruker by 4,510.3% in the fourth quarter. Marshall Wace LLP now owns 783,988 shares of the medical research company's stock valued at $45,957,000 after acquiring an additional 766,983 shares during the period. Hedge funds and other institutional investors own 79.52% of the company's stock.

Bruker Stock Down 2.3%

Shares of Bruker stock traded down $0.73 on Friday, reaching $30.43. The stock had a trading volume of 3,943,871 shares, compared to its average volume of 4,038,396. The company has a 50 day moving average price of $39.45 and a 200 day moving average price of $42.65. The company has a quick ratio of 0.74, a current ratio of 1.61 and a debt-to-equity ratio of 1.31. Bruker Corporation has a 1 year low of $30.19 and a 1 year high of $72.94. The stock has a market capitalization of $4.62 billion, a P/E ratio of 58.52, a P/E/G ratio of 2.58 and a beta of 1.16.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The medical research company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The firm had revenue of $797.40 million during the quarter, compared to analysts' expectations of $811.17 million. Bruker had a return on equity of 17.89% and a net margin of 2.31%. The firm's quarterly revenue was down .4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.52 EPS. As a group, equities research analysts forecast that Bruker Corporation will post 2.69 EPS for the current year.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Monday, June 16th were paid a $0.05 dividend. The ex-dividend date was Monday, June 16th. This represents a $0.20 dividend on an annualized basis and a yield of 0.7%. Bruker's dividend payout ratio (DPR) is 38.46%.

Insider Buying and Selling

In other Bruker news, CEO Frank H. Laukien acquired 2,608 shares of the firm's stock in a transaction on Friday, June 6th. The stock was acquired at an average cost of $38.36 per share, for a total transaction of $100,042.88. Following the purchase, the chief executive officer owned 38,462,171 shares in the company, valued at approximately $1,475,408,879.56. The trade was a 0.01% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 27.30% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

BRKR has been the topic of several recent analyst reports. Barclays reduced their target price on shares of Bruker from $46.00 to $43.00 and set an "overweight" rating on the stock in a research note on Monday, August 4th. Bank of America cut their price target on shares of Bruker from $61.00 to $50.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. Citigroup cut their price target on shares of Bruker from $40.00 to $38.00 and set a "neutral" rating on the stock in a report on Monday, August 4th. Jefferies Financial Group set a $60.00 price target on shares of Bruker and gave the stock a "buy" rating in a report on Monday, August 4th. Finally, The Goldman Sachs Group cut their price target on shares of Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. Six analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $51.30.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.